Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …

During cancer progression, tumor cells undergo molecular and phenotypic changes
collectively referred to as cellular plasticity. Such changes result from microenvironmental …

The determination of molecular features that mediate clinically aggressive phenotypes in
prostate cancer remains a major biological and clinical challenge,. Recent advances in …

Inactivation of the RB1 tumor suppressor gene is common in several types of therapy-
resistant cancers, including metastatic castration-resistant prostate cancer, and predicts poor …

The lack of in vitro prostate cancer models that recapitulate the diversity of human prostate
cancer has hampered progress in understanding disease pathogenesis and therapy …

Lung cancer is the most common cause of cancer deaths worldwide. The two broad
histological subtypes of lung cancer are small-cell lung cancer (SCLC), which is the cause of …

Prostate cancer is the second-leading cause of cancer-related mortality in men in Western
societies. Androgen receptor (AR) signaling is a critical survival pathway for prostate cancer …

Prostate cancer is a hormone-dependent malignancy, whose onset and progression are
closely related to the activity of the androgen receptor (AR) signaling pathway. Due to this …

Emerging data demonstrate homologous recombination (HR) defects in castration-resistant
prostate cancers, rendering these tumours sensitive to PARP inhibition. Here we …

A mechanistic understanding of how mitochondrial dysfunction contributes to cell growth
and tumorigenesis is emerging beyond Warburg as an area of research that is under …